CXCR4 Up-Regulation by Imatinib Induces Chronic Myelogenous Leukemia (CML) Cell Migration to Bone Marrow Stroma and Promotes Survival of Quiescent CML Cells

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-07-0042
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Chronic Myelogenous Leukaemia (CML)

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2011English

Lonafarnib Reduces the Resistance of Primitive Quiescent CML Cells to Imatinib Mesylate in Vitro

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2005English

Downregulation of Γ-Catenin Inhibits CML Cell Growth and Potentiates the Response of CML Cells to Imatinib Through Β-Catenin Inhibition

International Journal of Molecular Medicine
MedicineGenetics
2012English

Characteristics of Dasatinib- And Imatinib-Resistant Chronic Myelogenous Leukemia Cells

Clinical Cancer Research
Cancer ResearchOncology
2008English

CML: Langzeitresultate Zum Imatinib-Stopp

Im Focus Onkologie
2017English

Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway

Frontiers in Oncology
Cancer ResearchOncology
2019English

Suboptimal Responses to Imatinib in Chronic Myelogenous Leukemia

Clinical Journal of Oncology Nursing
Oncology
2009English

66. Identification and Characterization of a B Cell Aptamer That Targets Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Myelogenous Leukemia (CML)

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2015English

Increased Cortical Bone Mineralization in Imatinib Treated Patients With Chronic Myelogenous Leukemia

Haematologica
Hematology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy